Top Stories · October 8, 2026
FDA says its abortion pill safety review will continue into next year
CadNews does not determine absolute truth or endorse political viewpoints. It compares publicly available reporting, identifies shared facts, highlights framing differences, and flags uncertainty.
About these outlets
Neutral Summary
The Food and Drug Administration (FDA) has announced that its safety review of the abortion pill mifepristone will extend into early 2027. Following an order from Health Secretary Robert F. Kennedy Jr., the agency expects to complete a safety study by mid-December 2025, with a final report and potential regulatory decisions expected by March 2027. This timeline has drawn criticism from anti-abortion groups seeking immediate restrictions, while the agency continues to utilize statistical data mining to evaluate potential unknown safety concerns. The review occurs amidst ongoing litigation in the 5th U.S. Circuit Court of Appeals regarding state-level challenges to mail-order access.
The Food and Drug Administration (FDA) has announced that its safety review of the abortion pill mifepristone will extend into early 2027. Following an order from Health Secretary Robert F. Kennedy Jr., the agency expects to complete a safety study by mid-December 2025, with a final report and potential regulatory decisions expected by March 2027. This timeline has drawn criticism from anti-abortion groups seeking immediate restrictions, while the agency continues to utilize statistical data mining to evaluate potential unknown safety concerns. The review occurs amidst ongoing litigation in the 5th U.S. Circuit Court of Appeals regarding state-level challenges to mail-order access.